利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

21 条记录 (耗时 0.026 秒)

    Nucleic acids and polypeptides which resemble Rho and which interact with cell signalling pathways and proteins
    2.
    发明授权
    Nucleic acids and polypeptides which resemble Rho and which interact with cell signalling pathways and proteins 失效
    核酸和多肽类似于Rho并与细胞信号通路和蛋白质相互作用

    公开(公告)号：US07442534B2

    公开(公告)日：2008-10-28

    申请号：US10330372

    申请日：2002-12-27

    申请人： Arie Abo ,  Ami Aronheim

    发明人： Arie Abo ,  Ami Aronheim

    IPC分类号： C12N9/14 ,  C07K14/47

    CPC分类号： C12N9/16 ,  C07K2319/00

    摘要： The present invention relates to an isolated full-length Chp polypeptide, a biologically-active polypeptide fragment thereof, and nucleic acids which code for it. This polypeptide has various activities in regulating cell signaling and signal transduction pathways, including, e.g., a PAK regulatory domain binding activity, a PAK kinase stimulatory activity, a JNK kinase stimulatory activity, a cytoskeletal-reorganizing activity, or a Chp-specific immunogenic activity. The invention relates to all aspects of Chp, or homologs thereof, including assays for modulators, activators, ligands, etc.

    摘要翻译： 本发明涉及分离的全长Chp多肽，其生物活性多肽片段和编码它的核酸。 该多肽在调节细胞信号传导和信号转导途径中具有多种活性，包括例如PAK调节结构域结合活性，PAK激酶刺激活性，JNK激酶刺激活性，细胞骨架重组活性或Chp特异性免疫原性活性 。 本发明涉及Chp或其同系物的所有方面，包括调节剂，活化剂，配体等的测定。

    Human PAK65
    3.
    发明授权
    Human PAK65 失效
    人类PAK65

    公开(公告)号：US5698428A

    公开(公告)日：1997-12-16

    申请号：US780833

    申请日：1997-01-10

    申请人： Arie Abo ,  George A. Martin

    发明人： Arie Abo ,  George A. Martin

    IPC分类号： G01N33/566 ,  A61K31/70 ,  A61K38/55 ,  A61P25/00 ,  A61P29/00 ,  A61P35/02 ,  A61P37/00 ,  C12N5/10 ,  C12N9/12 ,  C12N15/09 ,  C12P21/04 ,  G01N33/15

    CPC分类号： C12N9/1205

    摘要： A novel human serine protein kinase, human p21-protein activated serine kinase p65 protein, referred to as hPAK65, and methods for its preparation and use are provided. Nucleic acids encoding hPAK65 and methods for their use in preparing hPAK65 as well as in preparing and identifying hPAK65 analogs are provided. Methods provided for the use of hPAK65 protein and its protein fragments, such as those that retain at least one hPAK65 activity, that include screening libraries of agents for candidates that modulate hPAK65 activity. Methods are provided to identify agents that modulate the interaction of hPAK65 with rho-like p21 GTPases, particularly rac1 and CDC42Hs binding to hPAK65 and subsequent activation of hPAK65 serine protein kinase activity, that modulate hPAK65 serine protein kinase activity, and that modulate hPAK65 effect on p21 protein GTPase activity. Such modulating agents can provide novel chemotherapeutic agents for treatment of neoplasia, lymphoproliferative conditions, arthritis, inflammation, autoimmune diseases, apoptosis, and the like, that are related to hPAK65 and p21 protein signal transduction pathways.

    摘要翻译： 提供了一种新的人丝氨酸蛋白激酶，人p21蛋白激活的丝氨酸激酶p65蛋白，被称为hPAK65，以及其制备和使用方法。 提供编码hPAK65的核酸及其制备hPAK65以及制备和鉴定hPAK65类似物的方法。 提供使用hPAK65蛋白及其蛋白质片段（例如保留至少一种hPAK65活性的蛋白质片段）的方法，包括筛选调节hPAK65活性的候选物的试剂库。 提供方法来鉴定调节hPAK65与rho样p21GTP酶，特别是结合hPAK65的rac1和CDC42H以及随后激活hPAK65丝氨酸蛋白激酶活性的调节hPAK65丝氨酸蛋白激酶活性的相互作用的试剂，并调节hPAK65对hPAK65的影响 p21蛋白GTPase活性。 这些调节剂可以提供用于治疗与hPAK65和p21蛋白信号转导途径有关的肿瘤形成，淋巴组织增生病症，关节炎，炎症，自身免疫性疾病，凋亡等的新型化学治疗剂。

    Antibodies to CLL-1
    4.
    发明授权
    Antibodies to CLL-1 有权
    CLL-1抗体

    公开(公告)号：US08536310B2

    公开(公告)日：2013-09-17

    申请号：US12738546

    申请日：2008-10-03

    申请人： Arie Abo ,  Wouter Korver

    发明人： Arie Abo ,  Wouter Korver

    IPC分类号： C12P21/08

    CPC分类号： C07K16/2851 ,  A61K2039/505 ,  C07K16/3061 ,  C07K2317/24 ,  C07K2317/56 ,  C07K2317/734 ,  C07K2317/77 ,  C07K2317/92 ,  C07K2319/21

    摘要： Anti-CLL-1 antibodies and antigen-binding fragments thereof, as well as pharmaceutical compositions comprising such antibodies and antigen-binding fragments are described. Also described are methods of using such antibodies and antigen-binding regions to bind CLL-1 and treat diseases, such as hematologic malignancies, which are characterized by expression of CLL-1.

    摘要翻译： 描述了抗CLL-1抗体及其抗原结合片段，以及包含此类抗体和抗原结合片段的药物组合物。 还描述了使用这些抗体和抗原结合区域结合CLL-1并治疗以CLL-1表达为特征的疾病如血液恶性肿瘤的方法。

    Human PAK65
    7.
    发明授权
    Human PAK65 失效

    公开(公告)号：US5518911A

    公开(公告)日：1996-05-21

    申请号：US369780

    申请日：1995-01-06

    申请人： Arie Abo ,  George A. Martin

    发明人： Arie Abo ,  George A. Martin

    IPC分类号： G01N33/566 ,  A61K31/70 ,  A61K38/55 ,  A61P25/00 ,  A61P29/00 ,  A61P35/02 ,  A61P37/00 ,  C12N5/10 ,  C12N9/12 ,  C12N15/09 ,  C12P21/04 ,  G01N33/15 ,  C07H21/04 ,  C12N1/20 ,  C12P21/06

    CPC分类号： C12N9/1205

    摘要： A novel human serine protein kinase, human p21-protein activated serine kinase p65 protein, referred to as hPAK65, and methods for its preparation and use are provided. Nucleic acids encoding hPAK65 and methods for their use in preparing hPAK65 as well as in preparing and identifying hPAK65 analogs are provided. Methods provided for the use of hPAK65 protein and its protein fragments, such as those that retain at least one hPAK65 activity, that include screening libraries of agents for candidates that modulate hPAK65 activity. Methods are provided to identify agents that modulate the interaction of hPAK65 with rho-like p21 GTPases, particularly rac1 and CDC42Hs binding to hPAK65 and subsequent activation of hPAK65 serine protein kinase activity, that modulate hPAK65 serine protein kinase activity, and that modulate hPAK65 effect on p21 protein GTPase activity. Such modulating agents can provide novel chemotherapeutic agents for treatment of neoplasia, lymphoproliferative conditions, arthritis, inflammation, autoimmune diseases, apoptosis, and the like, that are related to hPAK65 and p21 protein signal transduction pathways.